Catalog No.: PC-21894Not For Human Use, Lab Use Only.
Tuvutromstat (IDE397, GSK4362676, GSK-676) is a potent, selective small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts.
Tuvutromstat (IDE397, GSK4362676, GSK-676) is a potent, selective small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts.
IDE397 produces a dose- and time-dependent modulation of the proximal and distal PD biomarkers SAM and symmetrically di-methylates arginine (SDMA) in HCT116 MTAP-deleted CDX model.
HCT116 MTAP-deleted CDX model is more sensitive to IDE397 compared to the HCT116 MTAP-WT model.
IDE397 displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts. exhibits anti-tumor activity as a single agent in MTAP-deleted CDX models and in MTAP-deleted PDX models of NSCLC, pancreatic, bladder, head and neck, esophageal and gastric cancer.
1. Marcus M. Fischer, et al. Cancer Res (2021) 81 (13_Supplement): 1278. 2. Zihan Shi, et al. J Med Chem. 2025 Nov 27;68(22):24213-24231. 3. Patent WO2022256808 A1 2022-12-08.
